Navigation Links
Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Date:8/13/2008

Orchid Pharma partners with Diakron

MORRIS PLAINS, N.J., Aug. 13 /PRNewswire/ -- Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

In a simultaneous transaction, Orchid Chemicals & Pharmaceuticals Ltd., the Chennai (India) based pharmaceutical major ("Orchid Pharma"), has signed an agreement to partner with Diakron as a significant shareholder and developer for the anticoagulant drug candidate. Orchid will be undertaking the next stages of development.

Announcing the successful conclusion of the agreements, Srirama Rao, PhD., a founder and the Chairman of Diakron said, "We are extremely pleased to be able to license this compound from Merck for further development and commercialization. We are also pleased that Orchid is partnering with us as a significant shareholder and developer of this compound, leveraging its world-class R&D infrastructure in India. This will allow Diakron to fast-track development of this unique anticoagulant product as its number one priority."

Commenting on the agreement, Dr. C.B. Rao, Deputy Managing Director of Orchid stated that partnering with Diakron for the development of this Merck compound is a significant development in Orchid's drug discovery journey. With its end-to-end drug discovery and drug development capability backed by US FDA and UK MHRA compliant manufacturing facilities, Orchid is well positioned to support the development of the compound all the way to successful commercialization, he observed.

"Despite recent advances there remains a significant unmet medical need for novel anticoagulant therapies," said Joseph Vacca, Executive Director of Medic
'/>"/>

SOURCE Diakron Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Genetics Determine Optimal Drug Dose of Common Anticoagulant
5. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), a ... that Thomas M. Patton , President and ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at ... . The presentation is scheduled to begin ... will be available via a live webcast at http://wsw.com/webcast/marcum/casm/ ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Company (NYSE: ADM ) is pleased to ... effects of soy isoflavones in the alleviation of menopausal ... by Menopause: The Journal of The North American ... soy isoflavone supplements, like NovaSoy brand soy isoflavones, are ...
... /PRNewswire-iReach/ -- Global BioClinical (GBC) the Seattle-based contract ... a new website at www.globalbioclinical.com . The ... offered, partner registration, new search capabilities, and links ... The service descriptions function as a benchmark ...
Cached Medicine Technology:Study Confirms Soy Isoflavones Reduce Menopausal Hot Flashes 2Study Confirms Soy Isoflavones Reduce Menopausal Hot Flashes 3Global BioClinical Launches New Website 2
(Date:5/23/2013)... Camden, New Jersey (PRWEB) May 23, 2013 ... million Americans suffering from irritable bowel syndrome (IBS), the ... damper on your holiday fun. , “While hot dogs ... picnic plate during the warm weather months, IBS sufferers ... foods,” says Deborah Sokol, MD, a gastroenterologist with Lourdes ...
(Date:5/23/2013)... City, UT (PRWEB) May 23, 2013 ... , a comprehensive radiology learning environment for all ... prebuilt lessons and assessments, transforms the learning experience ... radiology curriculum. , “Until RADPrimer 3.0, ... second to none,” comments Dr. B.J. Manaster, Professor ...
(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Transvaginal ... Bard, Inc., continue to move forward in a federal ... of West Virginia, Bernstein Liebhard LLP reports. In ... a request by C.R. Bard to seal emails that ... secrets and other confidential, proprietary information about its suppliers. ...
Breaking Medicine News(10 mins):Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3
... of Knowledge Award in the Biomedicine category goes in ... New York, United States), investigator in the Department of ... granted, in the words of the jury, "for his ... the largest, most versatile and most therapeutically accessible receptor ...
... research , WEDNESDAY, Jan. 27 (HealthDay News) -- Same-sex couples ... couples are, a review of 20 years of social science ... out there that children need both a mother and a ... professor of sociology and of social and cultural analysis at ...
... ... ... 27, 2010 -- Epocrates, Inc. and RealCME announced today ... an advanced technology platform that addresses the needs of CME providers, supporters and health ...
... ... and 104E industrial computers.,Percon rejoins the AIDC and industrial computer industries with their release of ... data terminals or fixed mount computers are designed to operate in the harshest of environments. ... (PRWEB) January 27, ...
... Interest in whether ... New York, medical malpractice attorneys say. , ... New York, NY (PRWEB) January 27, 2010 -- Medical professionals of any kind ... standards of practice in the medical community. Unfortunately, a number of issues may compromise this ...
... ... with over 30 years combined experience in the hospitality industry. Their knowledge of writing ... Hakuna combines the mind of a manger with the speed and processing power of ... (PRWEB) January ...
Cached Medicine News:Health News:Lefkowitz, BBVA Foundation Frontiers of Knowledge Award in Biomedicine 2Health News:Lefkowitz, BBVA Foundation Frontiers of Knowledge Award in Biomedicine 3Health News:Are Two Mommies as Good as Mom and Dad? 2Health News:Are Two Mommies as Good as Mom and Dad? 3Health News:Are Two Mommies as Good as Mom and Dad? 4Health News:Epocrates and RealCME Unite to Deliver Enhanced e-Learning Offerings 2Health News:Epocrates and RealCME Unite to Deliver Enhanced e-Learning Offerings 3Health News:Percon Delivers Maximum Value in New Industrial Vehicle Computer Products 2Health News:Tired Doctors Need More Rest According to New York Medical Malpractice Attorney, David Perecman 2Health News:Tired Doctors Need More Rest According to New York Medical Malpractice Attorney, David Perecman 3Health News:Hakuna Staff Scheduling Software is Proud To Announce the Launch of Its Online Employee Scheduling Program 2
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... Sugar-Chex Linearity is a whole blood ... reportable range of the most popular ... recommendations of using a control matrix ... Linearity is packaged in ready-to-use dropper ...
Medicine Products: